S&P Futures
6,010.00 +23.00 (+0.38%) Dow Futures
44,598.00 +203.00 (+0.46%) Nasdaq Futures
20,951.25 +101.50 (+0.49%) Russell 2000 Futures
2,444.20 +30.60 (+1.27%) Crude Oil
71.30 +0.06 (+0.08%) Gold
2,715.20 +3.00 (+0.11%)
QuidelOrtho Corporation (QDEL)
After hours:
| Previous Close | 37.89 |
| Open | 37.89 |
| Bid | 37.50 x 200 |
| Ask | 40.35 x 400 |
| Day's Range | 37.49 - 40.81 |
| 52 Week Range | 29.74 - 75.86 |
| Volume | |
| Avg. Volume | 805,653 |
| Market Cap | 2.7B |
| Beta (5Y Monthly) | 0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -27.81 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.50 |
Business WireQuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group
SAN DIEGO, November 20, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the "Offering") by Carlyle Partners VI Cayman Holdings, L.P. (the "Selling Stockholder") of 8,260,183 shares of the Company’s common stock ("Common Stock").
Business WireQuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group
SAN DIEGO, November 19, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the "Offering") by Carlyle Partners VI Cayman Holdings, L.P. (the "Selling Stockholder") of 8,260,183 shares of the Company’s common stock ("Common Stock").
